BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Philippe R, Urbach V. Specialized Pro-Resolving Lipid Mediators in Cystic Fibrosis. Int J Mol Sci 2018;19:E2865. [PMID: 30241412 DOI: 10.3390/ijms19102865] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Mangiarotti A, Genovese DM, Naumann CA, Monti MR, Wilke N. Hopanoids, like sterols, modulate dynamics, compaction, phase segregation and permeability of membranes. Biochimica et Biophysica Acta (BBA) - Biomembranes 2019;1861:183060. [DOI: 10.1016/j.bbamem.2019.183060] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
2 Maciuszek M, Cacace A, Brennan E, Godson C, Chapman TM. Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential. Eur J Med Chem 2021;213:113167. [PMID: 33486199 DOI: 10.1016/j.ejmech.2021.113167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
3 Briottet M, Shum M, Urbach V. The Role of Specialized Pro-Resolving Mediators in Cystic Fibrosis Airways Disease. Front Pharmacol 2020;11:1290. [PMID: 32982730 DOI: 10.3389/fphar.2020.01290] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Naqvi RA, Gupta M, George A, Naqvi AR. MicroRNAs in shaping the resolution phase of inflammation. Semin Cell Dev Biol 2021:S1084-9521(21)00066-5. [PMID: 33934990 DOI: 10.1016/j.semcdb.2021.03.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
5 Strandvik B. Nutrition in Cystic Fibrosis—Some Notes on the Fat Recommendations. Nutrients 2022;14:853. [DOI: 10.3390/nu14040853] [Reference Citation Analysis]
6 Sandhaus S, Swick AG. Specialized proresolving mediators in infection and lung injury. Biofactors 2021;47:6-18. [PMID: 33249673 DOI: 10.1002/biof.1691] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Mehta M, Dhanjal DS, Paudel KR, Singh B, Gupta G, Rajeshkumar S, Thangavelu L, Tambuwala MM, Bakshi HA, Chellappan DK, Pandey P, Dureja H, Charbe NB, Singh SK, Shukla SD, Nammi S, Aljabali AA, Wich PR, Hansbro PM, Satija S, Dua K. Cellular signalling pathways mediating the pathogenesis of chronic inflammatory respiratory diseases: an update. Inflammopharmacol 2020;28:795-817. [DOI: 10.1007/s10787-020-00698-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
8 Zielen S, Fussbroich D. Impact of secondhand smoke on cystic fibrosis: is there a link to fatty acid metabolism? Thorax 2019;74:529-30. [PMID: 31048510 DOI: 10.1136/thoraxjnl-2019-213042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Léveillé P, Knoth IS, Denis MH, Morin G, Barlaam F, Nyalendo C, Daneault C, Marcotte JE, Rosiers CD, Ferland G, Lippé S, Mailhot G. Association between fat-soluble nutrient status and auditory and visual related potentials in newly diagnosed non-screened infants with cystic fibrosis: A case-control study. Prostaglandins Leukot Essent Fatty Acids 2019;150:21-30. [PMID: 31568924 DOI: 10.1016/j.plefa.2019.09.003] [Reference Citation Analysis]
10 Hiram R, Xiong F, Naud P, Xiao J, Sirois M, Tanguay JF, Tardif JC, Nattel S. The inflammation-resolution promoting molecule resolvin-D1 prevents atrial proarrhythmic remodelling in experimental right heart disease. Cardiovasc Res 2021;117:1776-89. [PMID: 32866246 DOI: 10.1093/cvr/cvaa186] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
11 Touboul D, Ollero M. Lipidomics Conquers a Niche, Consolidates Growth. Int J Mol Sci 2019;20:E3188. [PMID: 31261848 DOI: 10.3390/ijms20133188] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
12 Brennan E, Mohan M, Andrews D, Bose M, Kantharidis P. Specialized pro-resolving mediators in diabetes: novel therapeutic strategies. Clinical Science 2019;133:2121-41. [DOI: 10.1042/cs20190067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
13 Fanti F, Oliva E, Tortolani D, Di Meo C, Fava M, Leuti A, Rapino C, Sergi M, Maccarrone M, Compagnone D. μSPE followed by HPLC-MS/MS for the determination of series D and E resolvins in biological matrices. J Pharm Biomed Anal 2021;203:114181. [PMID: 34111730 DOI: 10.1016/j.jpba.2021.114181] [Reference Citation Analysis]
14 Wheelock CE, Strandvik B. Abnormal n-6 fatty acid metabolism in cystic fibrosis contributes to pulmonary symptoms. Prostaglandins Leukot Essent Fatty Acids 2020;160:102156. [PMID: 32750662 DOI: 10.1016/j.plefa.2020.102156] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
15 Wasserman AH, Venkatesan M, Aguirre A. Bioactive Lipid Signaling in Cardiovascular Disease, Development, and Regeneration. Cells 2020;9:E1391. [PMID: 32503253 DOI: 10.3390/cells9061391] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
16 Brennan E, Kantharidis P, Cooper ME, Godson C. Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function. Nat Rev Nephrol 2021. [PMID: 34282342 DOI: 10.1038/s41581-021-00454-y] [Reference Citation Analysis]
17 Carnovale V, Castaldo A, Di Minno A, Gelzo M, Iacotucci P, Illiano A, Pinto G, Castaldo G, Amoresano A. Oxylipin profile in saliva from patients with cystic fibrosis reveals a balance between pro-resolving and pro-inflammatory molecules. Sci Rep 2022;12:5838. [PMID: 35393448 DOI: 10.1038/s41598-022-09618-7] [Reference Citation Analysis]